key: cord-0992734-aycxq76l authors: Tiwari, Shashi Kant; Wang, Shaobo; Smith, Davey; Carlin, Aaron; Rana, Tariq M. title: Revealing tissue-specific SARS-CoV-2 infection and host responses using human stem cell derived lung and cerebral organoids date: 2021-02-12 journal: Stem Cell Reports DOI: 10.1016/j.stemcr.2021.02.005 sha: d8d60850c7683e496a5311be5e883e6a6d0c8c74 doc_id: 992734 cord_uid: aycxq76l COVID-19 is a transmissible respiratory disease, caused by a novel coronavirus SARS-CoV-2, has become a global health emergency. There is an urgent need for robust and practical in vitro model systems to investigate viral pathogenesis. Here, we generated human iPSCs-derived lung organoids (LORGs), cerebral organoids (CORGs), neural progenitor cells (NPCs), neurons and astrocytes. LORGs containing epithelial cells, alveolar type 1 and type 2, highly express ACE2 and TMPRSS2 and are permissive to SARS-CoV-2 infection. SARS-CoV-2 infection induces IFNs, cytokines and chemokines and activates critical inflammasome pathway genes. Spike protein inhibitor, EK1 peptide, and TMPRSS2 inhibitors (camostat/nafamostat) block viral entry in LORGs. Conversely, CORGs, NPCs, astrocytes, and neurons express low levels of ACE2 and TMPRSS2 and correspondingly are not highly permissive to SARS-CoV-2 infection. Infection in neuronal cells activates TLR3/7, OAS2, complement system and apoptotic genes. These findings will aid in understanding COVID-19 pathogenesis and facilitate drug discovery. Coronavirus disease 2019 (COVID-19) is a transmissible respiratory disease, caused by a novel severe acute respiratory syndrome coronavirus SARS-CoV-2, has become a globe health emergency since it's outbreak in 2019 (Lu et al., 2020) . There are currently no approved drugs for this disease and there is an urgent need for developing therapeutic strategies. In addition, there is a lack of robust and practical in vitro model systems to investigate pathophysiology of COVID-19. The etiologic agent of COVID-19, SARS-CoV-2, is an enveloped positive-sense single-stranded RNA virus. SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) as a host cell receptor, and transmembrane serine protease 2 (TMPRSS2) to cleave its spike (S) protein for entry into the host cell (Hoffmann et al., 2020) . Symptoms of varies in severity and manifest in many ways involving multiple human organ systems. Due to the permissiveness of viral infection in various tissues, SARS-CoV-2 could lead to multiorgan failure and death (Puelles et al., 2020) . Our current understanding of COVID-19 disease is based on clinical outcomes and studies using cancer cell lines or transgenic mice models expressing ACE2 receptor for viral entry, which have limitations in recapitulating the human physiology to decipher fundamental molecular mechanisms regulating host-pathogen interactions, viral replication kinetics, and tropism. Thus, there is an urgent need for robust and practical in vitro model systems to investigate pathophysiology of SARS-CoV-2 infection. Induced pluripotent stem cells (iPSCs) or multipotent adults tissue stem cells can be differentiated to generate 3D complex organoid structures containing multiple cell types and assemblies that have characteristics of spatial organization and function of a tissue (Benito-Kwiecinski and Lancaster, 2019) . Organoids have shown great promise to model human diseases, investigate host-pathogen interactions, and for drug screening. In earlier studies, we and others have utilized ESC/iPSC derived human neuronal progenitor cells (hNPC) and cerebral organoids (CORG) to understand the Zika virus (ZIKV) associated neuronal injury (Dang et al., 2016; Dutta and Clevers, 2017; Muffat et al., 2018; Xu et al., 2016) . Recently, we reported glial cell diversity and methamphetamine-induced neuroinflammation in human cerebral organoids by using single cell RNA seq (Dang et al., 2020) . Several studies using stem cell derived organoids have started to provide further insights into SARS-CoV-2 infection of various cell types, host responses, and to discover new drug candidates Jacob et al., 2020; Katsura et al., 2020; Lamers et al., 2020; Mykytyn et al., 2021; Pellegrini et al., 2020; Ramani et al., 2020; Yang et al., 2020) . Interestingly, SARS-CoV-2 productively J o u r n a l P r e -p r o o f infects brain choroid plexus epithelium leading to cell death and functional deficits (Jacob et al., 2020; Pellegrini et al., 2020) . To investigate the tissue-specific SARS-CoV-2 infection and host responses in lungs and brain, we generated 3D human lung and cerebral organoids, and the brain cells types such as NPCs, neurons and astrocytes. By using a SARS-CoV-2 pseudovirus and USA-WA1/2020 SARS-CoV-2, we determined viral tropism, host responses, and viral inhibition by specific TMPRSS2 drugs and a spike protein binding peptide EK1. To develop a model system for investigating the human lung pathophysiology of SARS-CoV-2 infection, we differentiated stepwise human iPSCs into lung organoids (LORG) as described previously with minor modification (Leibel et al., 2019; Miller et al., 2019) . First, we differentiated human iPSC into definitive endoderm (DE) followed by specification into anterior foregut endoderm/spheroids (AFE), lung progenitor cells (LPC) and finally into lung organoids (Figures 1A, S1A, S1B). During differentiation, we characterized the authenticity of each step of differentiation into specific cell types. AFE in lung organoid medium by day 12 generated epithelial like structure and as the organoids progressively grow, mesenchymal populations became visible surrounding epithelial structures (Figures 1A and S1B). Next, AFE differentiation was confirmed by immunolabelling of AFE markers such as NK2 homeobox 1 (NKX2.1 + ) cells and western blotting of NKX2.1 to confirms their differentiation into AFE cells (Figures S1C, D) . In addition, AFE also contains progenitor cells like SOX2 + cells ( Figure S1D ). By day 60 (60D) in culture, human lung organoids have prominent epithelial structure as visualized by H & E staining ( Figure 1B ). During the development of 3D lung organoid, we detected expression of both proximal and distal regions of lung by SOX2 and SOX9, respectively ( Figure S1D ). These proximal and distal regions of lung contain epithelial cells specialized in diverse functions such as secretory, basal and ciliated cells in the airways and type I and II cells lining the alveoli (Barkauskas et al., 2017) . SOX9 expressing progenitors play a role in development of entire lung epithelium and are involved in formation of airway and alveolar cell types in lungs (Ostrin et al., 2018) . LORG epithelial cells (ECAD + ) were surrounded by mesenchymal cells as shown by vimentin (VIM) ( Figure 1C ). LORG also showed mesenchymal cells immunolabelling with smooth muscle marker, smooth muscle actin (SMA) and acetylated tubulin (ACTUB) ( Figure 1C ). Further, LORGs exhibit pseudostratified epithelial structures with P63+ basal like cells, J o u r n a l P r e -p r o o f lining the basal surfaces and population of ciliated cells such as FOXJ1+ cells ( Figure 1D ). Importantly, alveolar cell marker SFTPB and SFTPC showed co-labelling with SARS-CoV-2 receptor ACE2 and protease TMPRSS2 ( Figure 1E , F, and S1G). In addition, LORGs exhibit expression of alveolar type 1 markers AGER and HOPX ( Figure S1E Since SARS-CoV-2 uses ACE2 receptor and the transmembrane serine protease 2 (TMPRSS2) to cleave its spike (S) protein for entry into the cell, we quantified ACE2 and TMPRSS2 mRNA expression in iPSCs and LORGs. In addition, Hoffmann et al. showed that furin protease cleavage of spike protein at the S1/S2 site was essential for S-mediated cell-cell fusion and entry into human lung cells. We also included Dipeptidyl peptidase 4, DPP4, expression analysis that is a functional receptor for MERS-CoV. We analyzed the expression of host proteases and found a significant increase in expression of all these genes in lung organoids as compared to iPSCs and ACE2/PLASMIN increase was the highest, >10 fold ( Figure 1K and S1H). To confirm cell specific expression of ACE2 and TMPRSS2, we performed immunostaining of LORGs and our results showed that alveolar type 2 cells (SP-B and SP-C) expressed ACE2 and TMPRSS2 ( Figure 1E -F and S1G). Furthermore, western blot analysis of 60D old organoids showed strong protein expression of ACE2 and TMPRSS2 in alveolar type 2 cells ( Figure 1L ). Overall, these results demonstrate that LORGs express SARS- To determine whether lung organoids were permissive to SARS-CoV-2 infection, we constructed SARS-CoV-2 pseudovirus (GFP or Luciferase) based on VSV to investigate the viral entry process . We inoculated LORGs with SARS-CoV-2 pseudo virus (MOI=2) and at 24h post-infection analyzed for viral entry and infection based on EGFP signals ( Figure 2A ). Brightfield imaging of the whole LORG merged with robust EGFP signals as well as J o u r n a l P r e -p r o o f sections of LORG showed integration of EGFP, indicating successful incorporation of SARS-CoV-2 into organoids ( Figure 2A ). Further, SARS-CoV-2 showed co-labelling with ACE2 and TMPRSS2 indicating the virus binding with the receptor and internalization in the cell by TMPRSS2 proteases in LORG ( Figure 2B ). To quantify virus infection, we infected LORGs with SARS-CoV-2 pseudovirus expressing luciferase at an MOI of 2 for 24 hours. We observed a robust infection of organoids as quantified by luciferase activity ( Figure 2C ). To define the spike protein mediated and TMPRSS2 dependent SARS-CoV-2 infection of LORGs and to assess the utility of LORGs to test drugs that could inhibit viral infection, we treated LORGs with a fusion inhibition peptide EK1 targeting the HR1 domain of the spike protein and TMPRSS2 inhibitor camostat, and then quantified luciferase activity. We showed that camostat or EK1 peptide inhibited viral infection confirming that pseudovirus entry is mediated by the spike protein and is dependent on TMPRSS2 function ( Fig 2C) . As expected, combination of camostat and EK1 peptide robustly inhibited viral infection in LORGs ( Fig 2C) . Next, we compared these results with a lung epithelial cell line, Calu-3 and obtained similar results where EK1 peptide or TMPRSS2 inhibitors, camostat and nafamostat, repressed viral infection which was further reduced when both classes of inhibitors were combined ( Fig S1I) . Further, we tested the inhibitory activities of nafamostat in Calu-3 cells infected with a patient derived isolate of SARS-CoV-2 and our results showed that nafamostat significantly reduced SARS-CoV-2 infection (Figure S1J-K) as observed in LORG. These results, altogether, show that iPSC derived LORGs provide a 3D lung model system to evaluate S-mediated viral infection and drug efficacy to inhibit SARS-CoV-2. To determine the utility of the LORG model system for understanding the pathogenesis of SARS-CoV-2 infection, we used a patient derived isolate, SARS-CoV-2 USA-WA1/2020, for LORG infection. LORGs were infected with SARS-CoV-2 USA-WA1/2020 and infection rates were quantified by evaluating viral RNA of the infected cells and supernatants. We found that the viral strain productively infected LORGs and the infection rate was increased in a time dependent manner ( Figure 2D , E). To investigate physiological effects of virus infection, we examined the host response genes and we found that expression of a number of immune regulatory genes including STAT1, STAT2, interferons, and chemokines were upregulated in LORGs ( Figure 2F ). Our results showed that CCL5, CXCL10, IFNß, IL6 and IL8 were all J o u r n a l P r e -p r o o f upregulated >10 fold and these finding are consistent with the data obtained from SARS-CoV-2 infection of lung epithelial cells (Blanco-Melo et al., 2020) and COVID-19 patients relative to healthy donors (Daamen et al., 2020) . Interestingly, our results also indicate that SARS-CoV-2 infection activates the inflammasome pathway because the key genes of this pathway including NLRP3, ASC, IL-18 and caspase-1 were upregulated ( Figure 2G ). Altogether, our results demonstrate that SARS-CoV-2 robustly replicates in human lung organoids and provide a model system to study the mechanisms of viral pathogenesis as well as to test new therapeutics. Clinical case reports describe a wide range of neurological and neuropsychiatric manifestations in severe COVID-19 (Helms et al., 2020) . However, many questions remain about the COVID-19 and neurological manifestations: (a) Does SARS-CoV-2 infect brain? (b) Which cell types in brain are infected and support viral replication? (c) What are the host responses to infection and how does virus cause neuronal injury and observed phenotypes? To address these questions in a human relevant, in vitro model, we generated 3D cerebral organoids (CORGs) and investigated SARS-CoV-2 infection, which was based on the brain organoid we used to investigate ZIKA virus infection and methamphetamine associated neurotoxicity (Dang et al., 2020; Dang et al., 2016) . To understand the neurotropic potential of the SARS-CoV-2 virus, we differentiated human iPSCs into cerebral organoid, which showed presence of various cell types, such as neural progenitor cells (NPC), neurons, and glial cells characterized by their respective markers SOX-2, MAP-2 and GFAP ( Figure 3A , S2A-D). In addition, we differentiated iPSCs into NPCs, neurons, and astrocytes, as confirmed by their characteristic markers ( Figure S2B -D) . We also quantified the mRNA expression of neural progenitor genes (Nestin, SOX2, Figure S2B ), neuronal gene (MAP2, Figure S2C ) and glial genes (S100ß and GFAP, Figure S2D ) in 3D cerebral organoid and in 2D NPC, neurons and astrocytes. Next, to determine the potential of organoids and various cell types in brain to support SARS-CoV-2 infection, we determined ACE2 and TMPRSS2 expression in 3D cerebral organoids, as well as in differentiated NPCs, neurons, and astrocytes. qRT-PCR results showed that ACE2 and TMPRSS2 are expressed in cerebral organoids and in all three cell types analyzed including NPC, neurons, and astrocytes ( Figure 3B, C) . In addition, we analyzed the expression of host factors involved in entry and infection of SARS-CoV-2 such as FURIN, J o u r n a l P r e -p r o o f PLASMIN, CTSL1, NRP1 and DPP4 and found upregulation of these genes in cerebral organoids and astrocytes as compared to NSC ( Figure S2E ). We performed immunostaining to examine the expression of ACE2 and TMPRSS2 in organoids and ACE2/TMPRSS2 expression was readily detected with neuronal marker MAP2 ( Figure 3D ) and very low TMPRSS2 expression with glial cells GFAP ( Figure S2F-I) . These results show that cerebral organoids and three cell types analyzed express ACE2 and TMPRSS2, and interestingly, ACE2 and TMPRSS2 expression levels were the highest in CORGs followed by neurons and astrocytes. To determine whether CORGs were permissive to SARS-CoV-2 infection, we used SARS-CoV-2 pseudovirus (GFP or Luciferase) as described above for lung organoids. We Figure 3N ). Altogether, our results demonstrate that SARS-CoV-2 infects human cerebral organoids and regulate specific gene expressions in neurons involved in neuronal functions. We also show that iPSC derived organoids can be employed to study tissues-specific differences in supporting viral infection as well as inducing cell-specific host responses. SARS family of viruses including SARS-CoV-2, targets the human respiratory system leading to adverse effects, as observed in COVID-19 pandemic. However, the range of human tissues permissive to SARS-CoV-2 infection is wide and includes heart, brain, liver, and gastrointestinal system. To understand viral tropism and to investigate host-pathogen biology, we utilized iPSCderived lung and brain organoids to investigate SARS-CoV-2 infection and host responses. We found that alveolar epithelial cells highly expressed ACE2 and TMPRSS2 (Figures 1E, F, and K) and were permissive to SARS-CoV-2 infection and supported efficient replication kinetics ( Figure 2D and E). In addition, host factors such as neuropilin-1 (NRP1), cathepsin L (CTSL1), plasmin, and kallikrein-related peptidase 13 (KLK13) were expressed in both LORG and CORG model systems ( Figure 1K , S1H and S2E). In response to infection, most of the key genes in innate immunity, cytokine/chemokines, and inflammasome were upregulated in lung organoids ( Figure 2F and G). For example, immunity related genes include STAT1/2, IRF7, CCL5, CXCL10, TNFα, IL6, IL8, and interferon, which corroborate with the patient derived results indicating production of cytokines storm leading to severe lung injury. In addition, we found that SARS-CoV-2 infection of LORGs activated genes involved in inflammasome pathways (NLRP3, J o u r n a l P r e -p r o o f NLRC4, ASC, IL-18 and Caspase-1) suggesting that inflammasome activation causes the pulmonary inflammation and cell death in lungs. There is growing evidence of neurological complications in people with COVID-19 (Helms et al., 2020; Kremer et al., 2020; Mao et al., 2020) . However, the SARS-CoV-2 permissiveness of brain and specific cell types is not well established. Our results show that cerebral organoids express both ACE2 and TMPRSS2 and support virus infection. Corresponding to the lower expression of ACE2 and TMPRSS2 in cerebral organoids, we observed lower viral infection rates in cerebral organoids as compared with lung organoids (Figure 3B, C, and H) . Similarly, neurons expressed more ACE2 and TMPRSS2 than other cell types and were more permissive to viral infection than astrocytes and NPCs ( Figure 3B , C, F, G, I, J). In consistent with our results, two groups reported that SARS-CoV-2 does not infect neurons but efficiently infect choroid plexus epithelium leading to damage and cell death (Jacob et al., 2020; Pellegrini et al., 2020) . Interestingly, SARS-CoV-2 infection of neurons exhibited stimulation of gene expression different from lung organoids because we found TLRs, OAS, and IL06 but no interferons ( Figure 3K , L, S2J). Further, ZIKA, which is also a positive strand virus akin to SARS-CoV-2, also activates TLR3 to cause neuronal injury in NPCs (Dang et al., 2016) . In addition, complement system gene expression was strongly enhanced during SARS-CoV-2 infection, suggesting a potential mechanism for COVID-19 related symptoms where complement system is activated in response to injury, infection and neurodegenerative diseases and triggers the synaptic loss and neuronal cell death. Due to enhanced inflammatory response, neurons undergo apoptotic cell death as suggested by enhanced expression of caspase-3 and downregulation of anti-apototic genes, BCL2 and BX. Finally, we show that viral entry was S-mediated that was blocked by a specific inhibitor of spike protein, EK1 peptide, and TMPRSS2 inhibitors camostat and nafamostat in lung organoids ( Figure 2C ), Calu-3 cells (Figure S1 I-K). These results are in agreement previous studies showing the activities of EK1 peptide (Xia et al., 2020) and TMPRSS2 inhibitors (Hoffmann et al., 2020) in repressing SARS-CoV-2, further validating the utility of stem cell derived organoids to identify new therapeutics. Altogether, the described organoid model studies could facilitate the speed of drug discovery and provide useful knowledge about the mechanism of action and potential side effects of new drugs. All studies were performed based on the approved IRB protocols by the University of California, San Diego. Human iPSC cells were differentiated into lung and cerebral organoids by following the previously established methods (Leibel et al., 2019; Miller et al., 2019) with minor modifications. In brief, ~75-85% confluent undifferentiated hiPSC colonies were treated with 1 mg/mL dispase solution for 5-10 min at 37 0 C, washing cells gently with DMEM/F12 and scraping the colonies with a cell scraper in mTeSR TM1 medium. Next, iPSC colonies were dissociated into smaller colonies using serological pipette and plated 0.5mL of the smaller hiPSC clumps in 24well Matrigel coated plate. When cells reached to 50-75% of confluency, stepwise differentiation was started into definitive endoderm, anterior foregut endoderm and lung organoid differentiation. Cerebral organoids and were prepared as described previously (Dang et al., 2020; Dang et al., 2016) . Twenty 80 days organoids were transferred to bioreactors (125 ml (G) LORGs express lung epithelial cell markers EPCAM, ECAD and SPDEF. Mean ± SEM of n = 3 organoids cultured in different wells. *p < 0.05, **p < 0.01, by Student's t test. (H) Expression analysis of proximal lung epithelial cell markers (SOX9, FOXJ1, FOXA1, FOXA2, SCB1A1, MUC5B, KRT5, KRT8, ASCL3 and TP63) and progenitors cells genes (NKX2.1 and SOX2) expressed in developing lungs. Mean ± SEM of n = 3 organoids cultured in different wells. *p < 0.05, **p < 0.01, and ***p < 0.001, by Student's t test. (I) Analysis for lung alveolar type 1 cell (AT1) genes AGER and HOPX. Mean ± SEM of n = 3 organoids cultured in different wells. *p < 0.05 and ***p < 0.001. (J) Expression analysis for expression of lung alveolar type 2 cell (AT2) genes SFTPB, SFTPC, ABCA3 and SLC34A2. Mean ± SEM of n = 3 organoids cultured in different wells. *p < 0.05, **p < 0.01, and ***p < 0.001. J o u r n a l P r e -p r o o f Lung organoids: current uses and future promise Brain Organoids: Human Neurodevelopment in a Dish Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 Comprehensive Transcriptomic Analysis of COVID-19 Blood, Lung, and Airway Glial cell diversity and methamphetamine-induced neuroinflammation in human cerebral organoids Zika Virus Depletes Neural Progenitors in Human Cerebral Organoids through Activation of the Innate Immune Receptor TLR3 Organoid culture systems to study host-pathogen interactions Identification of SARS-CoV-2 inhibitors using lung and colonic organoids Neurologic Features in Severe SARS-CoV-2 Infection SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium Human Lung Stem Cell-Based Alveolospheres Provide Insights into SARS-CoV-2-Mediated Interferon Responses and Pneumocyte Dysfunction Neurologic and neuroimaging findings in COVID-19 patients: A retrospective multicenter study An Organoid-derived Bronchioalveolar Model for SARS-CoV-2 Infection of Human Alveolar-type II-like Cells Reversal of Surfactant Protein B Deficiency in Patient Specific Human Induced Pluripotent Stem Cell Derived Lung Organoids by Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease Generation of lung organoids from human pluripotent stem cells in vitro Human induced pluripotent stem cell-derived glial cells and neural progenitors display divergent responses to Zika and dengue infections SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site beta-Catenin maintains lung epithelial progenitors after lung specification SARS-CoV-2 Infects the Brain Choroid Plexus and Disrupts the Blood-CSF Barrier in Human Brain Organoids Multiorgan and Renal Tropism of SARS-CoV-2 SARS-CoV-2 targets neurons of 3D human brain organoids Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and coronaviruses by depleting membrane cholesterol Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids qRT-PCR analysis for 60D LORG shows expression of ACE2, TMPRSS2, DPP4 and Furin Western blot analysis of 60D old organoid showing protein levels for ECAD, SOX9, FOXJ1, MUC5AC and alveolar type 2 cells (Surfactant protein B, SP-B), SARS-CoV-2 receptor (ACE2) and protease (TMPRSS2) See also Figure S1 and Table S1 SARS-CoV-2 robustly replicates in human lung organoids and induces expression of genes involved in innate immunity and inflammation. (A) Phase contrast and fluorescence imaging shows infection of SARS-CoV-2-GFP pseudovirus Fluorescence image showing SARS-CoV-2 GFP pseudovirus infects ACE2 and TMPRSS2 + cells of the LORG. Scale bars= 100 μm and for enlarged image scale bar=50μm C) pseudo-SARS-CoV-2-Luciferase pseudovirus infection is blocked by viral entry inhibitors. Bar graph shows the luciferase activity in the presence and absence of TMPRSS2 inhibitor (Camostat mesylate) and a fusion inhibitor EK1 peptide to lung organoid infected with SARS Lung organoids were infected with SARS-CoV-2 USA-WA1/2020 virus at MOI of 2 and viral RNAs from supernatant (D) and cellular (E) LORGs were infected as above in (E) and gene expression of indicated genes was quantified by qRT-PCR at 72 hours post infection. Bar graph shows expression of immune response genes and cytokines (F) and inflammasome markers (G). Mean ± SEM B, C) qRT-PCR analysis shows expression of ACE2 and TMPRSS2 in CORG, NPCs, neurons, and astrocytes. Mean ± SEM of n = 3 independent organoids and n=3 independent experiments from NPCs, neurons and astrocytes. *p < 0.05 and **p < 0.01, by Student's t test White boxes were enlarged (right) and arrows show co-labelling of MAP-2/ACE2, MAP-2/TMPRSS2 in magnified images NPCs and neurons were infected with pseudo-SARS-CoV-2-GFP virus at MOI of 2 and analyzed after 24 h of infection. (E) Immunofluorescence and phase contrast images of an organoid showing SARS-CoV-2 (green) Scale bars represent 100 µm (Merged) and 25 µm (magnified). (G) Immunofluorescence confocal images of NPC differentiated neurons stained with antibody against β-Tubulin-III (Red) Organoids were infected with pseudo-SARS-CoV-2-Luciferase virus at MOI of 2 and NPCs, neurons and astrocytes were infected with SARS-CoV-2 USA-WA1/2020 virus at an MOI of 2 and viral RNAs from supernatant (I) and cellular (J) fractions Neurons were infected as above in (I-J) and gene expression of indicated genes was quantified by qRT-PCR at 48 hours post infection. Bar graph shows expression of innate We thank F. Furnari for the iPS cell lines and members of the Rana lab for helpful discussions and advice. The following reagent was deposited by the Centers for Disease Control and